Seres Therapeutics (MCRB) Stock Overview
A clinical-stage company, focuses on developing biotherapeutics for serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MCRB Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Seres Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.32 |
| 52 Week High | US$29.98 |
| 52 Week Low | US$6.53 |
| Beta | 0.29 |
| 1 Month Change | -33.24% |
| 3 Month Change | -44.46% |
| 1 Year Change | -35.83% |
| 3 Year Change | -91.34% |
| 5 Year Change | -97.88% |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'
Feb 06Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding
Nov 15
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Sep 23Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth
Jul 13Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth
May 08Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Shareholder Returns
| MCRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | -3.9% | -2.2% |
| 1Y | -35.8% | 22.8% | 16.9% |
Return vs Industry: MCRB underperformed the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: MCRB underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| MCRB volatility | |
|---|---|
| MCRB Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MCRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MCRB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 103 | Rich Kender | www.serestherapeutics.com |
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis.
Seres Therapeutics, Inc. Fundamentals Summary
| MCRB fundamental statistics | |
|---|---|
| Market cap | US$82.59m |
| Earnings (TTM) | US$5.39m |
| Revenue (TTM) | US$351.00k |
Is MCRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCRB income statement (TTM) | |
|---|---|
| Revenue | US$351.00k |
| Cost of Revenue | US$14.50m |
| Gross Profit | -US$14.15m |
| Other Expenses | -US$19.54m |
| Earnings | US$5.39m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | 0.60 |
| Gross Margin | -4,030.20% |
| Net Profit Margin | 1,536.75% |
| Debt/Equity Ratio | 0% |
How did MCRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 02:14 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Seres Therapeutics, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| John Newman | Canaccord Genuity |
| John Tanner | Cantor Fitzgerald & Co. |